{"id":"NCT00891046","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-na誰ve Patients With Active SJIA With and Without Fever.","officialTitle":"An Open-label Extension Study of Canakinumab (ACZ885) in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Active Systemic Manifestations Who Participated in Studies ACZ885G2301 and ACZ885G2305; and Response Characterization Study in Canakinumab Treatment-na誰ve Patients With Active SJIA With and Without Fever","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2009-04-30","resultsPosted":"2017-03-10","lastUpdate":"2019-03-26"},"enrollment":270,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Juvenile Idiopathic Arthritis"],"interventions":[{"type":"DRUG","name":"Canakinumab","otherNames":[]}],"arms":[{"label":"Canakinumab","type":"EXPERIMENTAL"}],"summary":"This open-label extension study will permit patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who previously were responsive to treatment with canakinumab and canakinumab treatment-na誰ve patients with active SJIA with and without fever to be retreated with 4 mg/kg s.c. every 4 weeks and assessed for continued efficacy and safety until discontinuation or when study CACZ885G2402 is in place at their study center or around March 2013, whichever occurs first. Patients who are steroid-free will be able to taper their canakinumab dose to 2 mg/kg s.c. every 4 weeks.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Treatment Related AEs and SAE","timeFrame":"From start of study treatment (Day 1) up to end of follow-up period (Week 271 for ACZ885 treated participants and Week 145 for ACZ885 treatment naive participants)","effectByArm":[{"arm":"ACZ885 Treatment Naive","deltaMin":108,"sd":null},{"arm":"ACZ885 Treated","deltaMin":137,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":73,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Peru","Poland","Russia","Spain","Sweden","Switzerland","Turkey (T端rkiye)","United Kingdom"]},"refs":{"pmids":["30269054","26314396"],"seeAlso":["http://www.novartisclinicaltrials.com","http://www.juvenilearthritisresearch.com"]},"adverseEventsSummary":{"seriousAny":{"events":47,"n":147},"commonTop":["Nasopharyngitis","Pyrexia","Cough","Rhinitis","Arthralgia"]}}